Evidence map›Paper›PMID 40593704›Full record

ArticleNature communications2025

Generation of mature epicardium derived from human-induced pluripotent stem cells via inhibition of mTOR signaling.

Yu Tian, Antonio Lucena-Cacace, Kanae Tani, Amanda Putri Elvandari, Rodolfo S Allendes Osorio, Megumi Narita, Yasuko Matsumura, Ian Costa Paixao, Yutaro Miyoshi, Azusa Inagaki and 2 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Elucidating Gene Functions in Congenital Heart Disease.Current treatment options in cardiovascular medicine · 2026
    Review
  6. Simultaneous Measurement of Contractile Force and CaSensors (Basel, Switzerland) · 2025
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yu Tian *Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0001-8042-9920
Antonio Lucena-Cacace *Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan. a.lucena.prime@osaka-u.ac.jp.ORCID http://orcid.org/0000-0002-1181-2683
Kanae TaniCenter for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0001-7006-7356
Amanda Putri ElvandariCenter for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0009-0004-0967-8114
Megumi NaritaCenter for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-8198-4042
Yasuko MatsumuraCenter for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0009-0009-1129-8694
Ian Costa PaixaoCenter for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0001-8594-2440
Yutaro MiyoshiCenter for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
Azusa InagakiCenter for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
Julia JunghofCenter for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
Yoshinori YoshidaCenter for iPS Cell Research and Application, Kyoto University, Kyoto, Japan. yoshinor@cira.kyoto-u.ac.jp.ORCID http://orcid.org/0000-0001-5511-9090

Funding

Japan Agency for Medical Research and Development (AMED) JP19bm0104001Japan Agency for Medical Research and Development (AMED) JP20bm0804022Japan Agency for Medical Research and Development (AMED) JP22mk0101241Japan Agency for Medical Research and Development (AMED) JP22ym0126091Japan Agency for Medical Research and Development (AMED) JP23bm1323001Japan Agency for Medical Research and Development (AMED) JP23bm1423011Japan Agency for Medical Research and Development (AMED) JP24bm1123054Japan Agency for Medical Research and Development (AMED) JP24mk0121280MEXT | Japan Science and Technology Agency (JST) JPMJSF2323MEXT | Japan Society for the Promotion of Science (JSPS) 21H02912MEXT | Japan Society for the Promotion of Science (JSPS) 22K16137MEXT | Japan Society for the Promotion of Science (JSPS) 24K11267
6 · The paper itself

Abstract

Reactivating the human epicardium post-cardiac injury holds promise for cardiac tissue regeneration. Despite successful differentiation protocols yielding pure, self-renewing epicardial cells from induced pluripotent stem cells (iPSCs), these cells maintain an embryonic, proliferative state, impeding adult epicardial reactivation investigation. We introduce an optimized method that employs mammalian target of rapamycin (mTOR) signaling inhibition in embryonic epicardium, inducing a quiescent state that enhances multi-step epicardial maturation. This yields functionally mature epicardium, valuable for modeling adult epicardial reactivation. Furthermore, we assess cardiac organoids with cardiomyocytes and mature epicardium, probing molecular mechanisms governing epicardial quiescence during cardiac maturation. Our results highlight iPSC-derived mature epicardium's potential in investigating adult epicardial reactivation, pivotal for effective cardiac regeneration. Additionally, the cardiac organoid model offers insight into intricate cardiomyocyte-epicardium interactions in cardiac development and regeneration.

Indexed as

Induced Pluripotent Stem CellsPericardiumTOR Serine-Threonine KinasesCell DifferentiationHumansMTOR InhibitorsMyocytes, CardiacOrganoidsRegenerationSignal TransductionMTOR InhibitorsMTOR protein, humanTOR Serine-Threonine Kinases

Identifiers

PMID40593704
PMCPMC12216149

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.